Alnylam Pharmaceuticals (ALNY) Shares are Up 1.57%

Alnylam Pharmaceuticals (ALNY) : Traders are bullish on Alnylam Pharmaceuticals (ALNY) as it has outperformed the S&P 500 by a margin of 12.96% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.95%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.57% in the last 1 week, and is up 20.59% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Alnylam Pharmaceuticals (NASDAQ:ALNY): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $65.24 and $64.58 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $65.85. The buying momentum continued till the end and the stock did not give up its gains. It closed at $65.49, notching a gain of 0.80% for the day. The total traded volume was 770,778 . The stock had closed at $64.97 on the previous day.


The stock has recorded a 20-day Moving Average of 8.03% and the 50-Day Moving Average is 7.34%. Alnylam Pharmaceuticals, Inc. has dropped 8.86% during the last 3-month period . Year-to-Date the stock performance stands at -30.43%.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics based on its ribonucleic acid interference (RNAi). The Companys pipeline focuses in three strategic therapeutic areas (STArs): Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, and hepatic infectious disease, with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), ALN-AT3, ALN-CC5, ALN-AS1, ALN-AAT, ALN-GO1, ALN-TMP, ALN-PCS, ALN-PCSsc, ALN-AC3, ALN-ANG, ANGPTL3, ALN-HBV, ALN-HDV and ALN-PDL. The Company is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *